Addus HomeCare (ADUS) Stock: Buy, Sell, or Hold?
ADUS - Addus HomeCare Corp.
$117.95
-0.08 (-0.07%)
▼
5d:
+1.14%
30d:
+3.25%
90d:
+5.39%
HOLD
MODERATE Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 03, 2026
11d
Get Alerted When ADUS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ADUS is fairly valued with market pricing in 2.4% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: ADUS is fairly valued with market pricing in 2.4% annual growth. Fine to hold or accumulate slowly on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$142.38
Based on 5.4% avg growth
INTRINSIC VALUE TODAY
$88.41
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ADUS is currently trading at $117.95, which is considered extended relative to its 30-day fair value range of $112.67 to $116.99. The stock's valuation (Forward PE: 15.7) is in line with its historical norms (14.6). At these levels, the market is pricing in 2.4% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ADUS is in a strong uptrend. The price is approaching resistance at $118.81. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 41/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $134.08 (+13.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ADUS is in a strong uptrend. The price is approaching resistance at $118.81. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 41/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $134.08 (+13.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$112.67 -
$116.99
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
49.5%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (41/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($134.08)
- NEUTRAL: Market pricing in 2.4% annual earnings growth - fairly valued
- NEUTRAL: Bottoming setup forming (41/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$112.67 -
$116.99
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$112.72
Resistance Level
$118.81
Current Trend
Strong Uptrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
15.69
Wall Street Target
$134.08
(+13.7%)
Revenue Growth (YoY)
8.0%
Earnings Growth (YoY)
24.2%
Profit Margin
7.1%
Valuation Premium vs History
+2.4% premium
PE vs Historical
15.7 vs 14.6
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.4%
(market-implied from PE analysis)
1-Year Target
$120.78
(+2%)
2-Year Target
$123.68
(+5%)
3-Year Target
$126.65
(+7%)
3-Yr Target (if PE normalizes)
(PE: 16→15)
PE COMPRESSION
$117.83
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 6.7%)
$181.15
(+54%)
Base:
(SPY PE: 15.7, Growth: 6.7%)
$143.13
(+21%)
Bear:
(PE: 13.3, Growth: 6.7%)
$121.66
(+3%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (21x PE), but valuation improves significantly next year (16x PE) as earnings recover.
Trailing PE: 20.67 | Current EPS (TTM): $5.71
Bull Case
$170.91
(+45%)
Analyst growth 31.6%, PE expands to 22.7
Base Case
$155.37
(+32%)
Market implied 31.6%, PE stable at 20.7
Bear Case
$80.26
(-32%)
Severe decline -20.0%, PE contracts to 17.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 22, 2026 6:29 AM ET
Data refreshes hourly during market hours. Next update: 7:29 AM
Data refreshes hourly during market hours. Next update: 7:29 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ADUS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Care Facilities Stocks
Top-rated stocks in Medical Care Facilities by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
THC
Tenet Healthcare Corpora… |
STRONG BUY
23 analysts |
$286 | 56 HOLD |
|
CMPS
Compass Pathways Plc |
STRONG BUY
16 analysts |
$24 | 60 HOLD |
|
HCA
HCA Healthcare, Inc. |
BUY
26 analysts |
$461 | 42 HOLD |
|
EHC
Encompass Health Corp |
STRONG BUY
13 analysts |
$148 | 59 HOLD |
|
GRDN
Guardian Pharmacy Servic… |
STRONG BUY
7 analysts |
$50 | 67 BUY |
